StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis USD Growth in Rest of World by Quarter

USD Growth in Rest of World (% USD) (%)

QuarterlyAnnual

Novartis USD Growth in Rest of World: -27.0% in Q3 2026, down 1.0 pts from a year earlier.

Latest, Q3 2026
-27.0%
Period ended Sep 30, 2026
Change on a year earlier
-1.0 pts
-26.0% in Q3 2025
History
32 quarters
Since Q4 2018
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

“|| Tasigna | Established brands | Chronic myeloid leukemia (CML) | 38 | – 52 | 103 | – 27 | – 29 | 141 | – 36 | – 37”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedUSD Growth in Rest of World (% USD) (%)Year on yearSource
Q3 2026Sep 30, 2026-27.0%-1.0 ptsNovartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026-32.0%-8.0 ptsNovartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026-29.0%-10.0 ptsNovartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025-32.0%-17.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025-26.0%-5.0 ptsNovartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 2025-24.0%-13.0 ptsNovartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 2025-19.0%-7.0 ptsNovartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 2024-15.0%-5.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024-21.0%-16.0 ptsNovartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024-11.0%+2.0 ptsNovartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024-12.0%-9.0 ptsNovartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 2023-10.0%-1.0 ptsNovartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 2023-5.0%+8.0 ptsNovartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 2023-13.0%-5.0 ptsNovartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 2023-3.0%+12.0 ptsNovartis Form 6-K (0001370368-23-000046) ↗
Q4 2022Dec 31, 2022-9.0%-4.0 ptsNovartis Form 6-K (0001370368-23-000008) ↗

Cite this data

StockData. (2026). Novartis USD Growth in Rest of World (%), quarterly Q4 2018–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-tasigna-row-yoy-usd-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.